Power3 Medical Products, Inc. (OTC:PWRM)
PWRM, a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced earlier this month that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, PWRM's diagnostic test, and focused on PWRM's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.
"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, PWRM's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."
"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of PWRM, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."
"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well.
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM's products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. PWRM's products analyze proteins and their mutations to assess an individual's risk for developing disease later in life or a patient's likelihood of responding to a particular drug; assess a patient's risk of disease progression and disease recurrence; and measure a patient's exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
Kayne Anderson Energy Development Company (NYSE:KED)
KED yesterday announced that it will report its earnings results for the quarter ended August 31, 2010 on Tuesday, October 12, 2010 after the financial markets close.
KED will host a conference call at 4:00 p.m. Central time on Tuesday, October 12, 2010 to discuss KED's results. All interested parties are welcome to participate. You can access the conference call by dialing (877) 563-8315 approximately 5-10 minutes prior to the call. International callers should dial (706) 679-4383. All callers should reference "Conference ID # 99686659." For the convenience of KED's stockholders, an archived replay of the call will be available on KED's website.
KED is a principal investment firm specializing in energy investments. KED prefers to invest in midstream energy companies. KED seeks to invest between $10 million and $75 million. KED typically invests in non-traded companies through equity and debt instruments. KED is based in Houston, Texas.
To learn more about KED visit: http://www.kaynebdc.com
Kayne Anderson Energy Total Return Fund, Inc. (NYSE:KYE)
KYE announced today its quarterly distribution of $0.48 per share for the period June 1, 2010 to August 31, 2010.
The distribution for the quarter ended August 31, 2010 will be payable on October 15, 2010 to common stockholders of record on October 5, 2010, with an ex-dividend date of October 1, 2010. It is anticipated that a significant portion of this distribution will be treated as a return of capital for tax purposes. The final determination of such amount will be made in early 2011 when KYE can determine its earnings and profits. The final tax status of the distribution may differ substantially from this preliminary information.
KYE is a closed ended balanced mutual fund launched by KA Fund Advisors, LLC. KYE is managed by Kayne Anderson Capital Advisors, L.P. KYE invests in the public equity and fixed income markets across the globe. KYE seeks to invest in the stocks of companies operating in the energy industry, primarily master limited partnerships (MLPs), MLP affiliates, energy-related U.S. and Canadian royalty trusts and income trusts, marine transportation and coal. KYE invests in the stocks of companies across all capitalizations. KYE employs a combination of fundamental, quantitative, and qualitative analysis with a focus on factors such as sound business fundamentals, a strong record of cash flow growth, a solid business strategy and a respected management team to create its portfolio. KYE was formed on June 28, 2005 and is domiciled in the United States.
To learn more about KYE visit: http://www.kaynefunds.com
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (OTC:PWRM). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (OTC:PWRM). Each advertising commitment has now expired.
Disclosure: No positions